A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic…

Overview of attention for article published in Investigational New Drugs, March 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 28 Mendeley

So far, Altmetric has seen 1 X post from an account with 2,307 followers.

A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors https://t.co/SSR1I7o7RP #hvhebron #onco

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.